Modulation of Sirtuin-1 by Resveratrol as a Potential Therapy in Alleviating Metabolic Syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and preclinical literature with no systematic review methodology or primary clinical trial data.
PubMed 41417203 · doi:10.1007/s12013-025-01955-4
What was done
This mini-review synthesized published evidence regarding the mechanisms through which trans-resveratrol interacts with sirtuin-1 (SIRT1) to influence metabolic pathways involved in metabolic syndrome.
What was found
The abstract reports qualitative mechanistic pathways without quantitative data or effect sizes. It describes that resveratrol-induced activation of SIRT1 modulates targets including peroxisome proliferator-activated receptor gamma coactivator-1 alpha, forkhead box protein O1, and AMP-activated protein kinase, leading to reported improvements in insulin sensitivity, mitochondrial biogenesis, obesity, dyslipidemia, and hypertension.
Why it matters
It organizes the molecular rationale for how SIRT1 activation by resveratrol might target multiple interconnected pathologies in metabolic syndrome.
Limits
This is a narrative mini-review with no original clinical data, systematic search protocol, or meta-analytic quantification. Human clinical translation, dosing feasibility, and bioavailability constraints are not evaluated in the abstract.
Cited by
- supports Resveratrol activates the sirtuin response and helps build mitochondria.